DK153709B - Analogifremgangsmaade til fremstilling af 4-substituerede piperidinoalkanolderivater - Google Patents
Analogifremgangsmaade til fremstilling af 4-substituerede piperidinoalkanolderivater Download PDFInfo
- Publication number
- DK153709B DK153709B DK132980AA DK132980A DK153709B DK 153709 B DK153709 B DK 153709B DK 132980A A DK132980A A DK 132980AA DK 132980 A DK132980 A DK 132980A DK 153709 B DK153709 B DK 153709B
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- compound
- alkyl
- piperidinyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
DK 153709B
o
Den foreliggende opfindelse angår en analogifremgangsmåde til fremstilling af hidtil ukendte 4-substitue-rede piperidinoalkanolderivater, der er anvendelige som antihistaminer, antiallergiske midler og bronchodilatorer, 5 hvilken fremgangsmåde er ejendommelig ved det i krav l's kendetegnende del angivne.
Beslægtede piperidinderivater med antihistamin-egenskaber findes beskrevet i US-patentskrifterne nr. 3.806.526, 3.829.433, 3.862.173, 3.878.217, 3.931.197, 3.941.795, 10 3.946.022 og 3.965.257.
De her omhandlede, hidtil ukendte 4-substituerede piperidinoalkanolderivater, der er anvendelige som antihistaminer, antiallergiske midler og bronchodilatorer, er forbindelser med formlen 15 99 C—OH ^ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
(V
OH CH, 2 KH2,3-CH-(3-C-r3 ch3 3
hvor J
4 3 5 R er -COOH eller -COO-alkyl, hvor alkylgruppen indeholder 6 7 1-6 carbonatomer og er ligekædet eller forgrenet, eller farmaceutisk acceptable salte af disse forbindelser.
8
De her omhandlede forbindelser med formlen (I) ud 9 viser en bedre antihistamin virkning end kendte, nært be 10 slægtede forbindelser.
11 12
Eksempler på ligekædede eller forgrenede alkylgrup- 13 per med 1-6 carbonatomer som nævnt ovenfor er methyl, ethyl, n-propyl, isopropyl, n-butyl, sek.butyl, tert.butyl, n--pentyl, neopentyl og n-hexyl.
14 3 15 Særligt foretrukne er de forbindelser, hvori R er 16 -COOH.
O
DK 153709B
2
De farmaceutisk acceptable syreadditionssalte af de fremstillede forbindelser er salte med enhver egnet u-organisk eller organisk syre. Ikke-toxiske salte af de fremstillede forbindelser med uorganiske og organiske ba-5 ser omfatter f.eks. saltene af alkalimetaller, såsom natrium, kalium og lithium, jordalkalimetallerne, f.eks. calcium og magnesium, de lette metaller af gruppen IIIA, f.eks. aluminium, samt organiske aminer såsom primære, sekundære og tertiære aminer, f.eks. cyclohexylamin, ethylamin, pyri-10 din, methylaminoethanol og piperazin. Saltene fremstilles på sædvanlig måde, f.eks. ved behandling af en forbindelse af formlen I med en passende syre eller base.
Forbindelserne af formel I er som nævnt anvendelige som antihistaminer, antiallergiske midler og bronchodila-15 torer og kan indgives alene eller sammen med passende farmaceutiske bærere i fast eller flydende form, f.eks. som tabletter, kapsler, pulvere, opløsninger, suspensioner eller emulsioner.
Den indgivne mængde kan variere over et bredt om-2o råde til tilvejebringelse i en enhedsdosis af en effektiv mængde på mellem ca. 0,01 og ca. 20 mg pr. kg legemsvægt om dagen til opnåelse af den ønskede virkning. Således kan f.eks. de ønskede virkninger opnås ved indgivning af en enhedsdosisform såsom en tablet indeholdende 1-50 mg af 25 den aktive forbindelse, taget 1-4 gange daglig.
Som eksempel på forbindelsernes anvendelighed kan nævnes, at 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]--1-hydroxybutyl]-α,α-dimethylbenzeneddikesyre i en koncen- _7 tration på 1 x 10 M giver en kendelig formindskelse af 30 histamin-fremkaldt sammentrækning af isolerede ileal- -muskler fra marsvin.
Forbindelserne af formlen I fremstilles ved en fremgangsmåde, ved hvilken den tilsvarende alkanon reduceres selektivt, hvorefter, om ønsket, en fremstillet for- 3 35 bindelse, hvori R er -COO-alkyl, omdannes til en forbm- 3 delse, hvori R er -COOH, ved base-hydrolyse, og/eller 3
DK 153709B
O
den dannede forbindelse omdannes til et farmaceutisk acceptabelt salt.deraf.
Af det følgende reaktionsskema vil det fremgå, at forbindelserne af formlen I kan fremstilles i et enkelt 5 trin ved reduktion af den tilsvarende keton eller i to trin ved reduktion af en passende keton efterfulgt af en base-hydrolyse afhængende af den ønskede forbindelse.
10 15 20 25 30 35
DK 153709B
4
REAKTIONSSKEMA I
B
O
O
ro O ro W I B u-u-u Φ s o = o /—V w ro
// \\ O M
H
>1 I
Η I * XS S w ^ 8 af 3 βΓ V BJ° g * Β-ύ-Β
4· Q
O-U Η M HH
I l_J Η-» H-|
„ η <Π H °-V
X>1J3-S- gSLKj >H N '
M
t. S
<* Ό O
w I o) j0 v
(Q M B I W
S · 0-0-0
*| +> J
(ti /xN K M I |1 m · L J)
(ti H
Z <D I
0=0
OsLK.? cr ^'
O
5
DK 153709B
I reaktionsskema I indeholder alkylgruppen i forbindelserne 4 og VIII 1-6 carbonatomer og er ligekædet eller forgrenet.
Reduktion af de forskellige forbindelser som vist i 5 reaktionsskema I under anvendelse af f.eks. natriumborhydrid eller kaliumborhydrid udføres i en lavere alkohol såsom methanol, ethanol, isopropylalkohol eller n-butanol. Disse reduktionsreaktioner udføres ved temperaturer fra ca. 0°C til tilbagesvalingstemperaturen for opløsningsmidlet, og 10 reaktionstiden varierer fra ca. 1/2 til ca. 8 timer.
Katalytisk reduktion kan også anvendes til fremstilling af forbindelserne af formlen I som vist i reaktionsskemaet under anvendelse af f.eks. Raney-nikkel-, palladium-, platin- eller rhodium-katalysatorer i lavere alko-15 holer såsom methanol, ethanol, isopropylalkohol eller n--butanol eller eddikesyre eller deres vandige blandinger, eller ved anvendelse af aluminiumisopropoxid i isopropylalkohol. Basisk hydrolyse af forbindelserne VIII til dannelse af forbindelserne X sker efter sædvanlige metoder, 2o f.eks. ved behandling med en uorganisk base såsom natriumeller kaliumhydroxid i en vandig lavere alkohol såsom vandig methanol, ethanol, isopropylalkohol eller n-butanol ved tilbagesvalingstemperatur i et tidsrum mellem ca. 1/2 og ca. 12 timer.
25 De keton-forbindelser, der anvendes som udgangsfor bindelser, dvs. forbindelserne 4 og 8 i reaktionsskema I fremstilles ved alkylering af et substitueret piperidin--derivat af formlen 00
Von tf
H
35 med en ω-halogenalkyl-substitueret phenylketon af formlen
O
DK 153709B
6 0 CH3 hal-(CH2)3-C-^^-C-R3 (XV) έκ3 5 i hvilke formler hal er halogen såsom chlor, brom eller 3 iod, og R er -COO-alkyl, hvor alkylgruppen indeholder 3 1-6 carbonatomer og er ligekædet eller forgrenet. Når R er -COOH, efterfølges alkyleringen af en base-hydrolyse.
10 Alkyleringen udføres i et passende opløsningsmiddel, for trinsvis i nærværelse af en base og eventuelt i nærværelse af en katalytisk mængde kaliumiodid over et tidsrum på mellem ca. 4 og ca. 120 timer og ved temperaturer mellem ca.
70°C og tilbagesvalingstemperaturen for opløsningsmidlet.
15 Eksempler på egnede opløsningsmidler til alkyleringsreak-tionen er alkoholer, f.eks. methanol, ethanol, isopropyl-alkohol og n-butanol, ketoner, f.eks. methylisobutylketon, qarbonhydrider, f.eks. benzen, toluen og xylen, og halogenerede carbonhydrider, f.eks. chlorbenzen eller methylenchlo-20 rid, samt dimethylformamid. Egnede baser til alkylerings-reaktionen omfatter uorganiske baser, f.eks. natriumbicar-bonat, kaliumcarbonat og kaliumbicarbonat, og organiske baser såsom trialkylaminer, f.eks. triethylamin, og pyri-din, men der kan også anvendes et overskud af en forbin-25 delse af formlen XIV. En base-hydrolyse af de forbindelser, 3 hvori R er -COO-alkyl, til dannelse af de tilsvarende forbindelser, hvori R er -COOH, opnås ved behandling med en uorganisk base som f.eks. natriumhydroxid i en vandig lavere alkohol såsom vandig methanol, ethanol, isopropyl-30 alkohol eller n-butanol ved tilbagesvalingstemperatur i et tidsrum mellem ca. 1/2 og ca. 12 timer.
Forbindelserne af formlen XIV kan fås i handelen. Forbindelserne af formlen XV fremstilles ved omsætning af en passende ligekædet eller forgrenet, lavere 35 alkyl-C^-Cg-ester af α,α-dimethylphenyleddikesyre, der er en kendt forbindelse eller kan fremstilles efter kendte metoder, med en forbindelse af formlen 0
O
DK 153709B
7 hal-(CH2)3-C-hal (XVII) hvori hal er som angivet ovenfor, under de generelle be-5 tingelser for en Friedel-Crafts-acylering. Denne reaktion udføres i et opløsningsmiddel såsom carbondisulfid, tetra-chlorethan eller nitrobenzen, hvoraf carbondisulfid er at foretrække. Reaktionstiden varierer fra ca. 1/2 til ca. 8, fortrinsvis fra ca. 3 til ca. 5 timer, og reaktionstempera-10 turen varierer fra ca. 0 til ca. 25°C.
Forbindelserne af formlen XVII fås i handelen eller kan fremstilles efter kendte metoder.
De følgende eksempler skal tjene til nærmere illustrering af fremgangsmåden ifølge opfindelsen.
15 EKSEMPEL 1
Ethyl-4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1--hydroxybuty 13 -ex,, α-dimethylbenzenacetat-hydrochlorid
En opløsning af 5,64 g (0,01 mol) ethyl-4-[4-[4-20 -(hydroxydiphenylmethyl)-1-piperidinyl]-1-oxohutyl]-α,α- -dimethylbenzenacetat-hydrochlorid i 200 ml absolut ethanol og 50 ml methanol og 0,5 g platinhydroxid hydrogene-res ved ca. 3,5 kg/cm i ca. 1 time, indtil IR ikke viser noget tegn på en keton-carbonylfunktion. Derefter filtre-25 res opløsningen, og filtratet inddampes, hvorefter om-krystallisation fra butanon og methanol/butanan giver ethyl-4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1--hydroxybutyl]-a,a-dimethylbenzenacetat, HC1 med smp.
185-187°C.
30 EKSEMPEL 2 4-[4-[4-(Hydroxydiphenylmethyl)-l-piperidinyl]-l-hydroxy-buty1]-a,a-dimethylbenzeneddikesyre
Til en opløsning af 0,6 g ethyl-4-[4-[4-(hydroxy-35 diphenylmethyl)-1-piperidinyl]-1-hydroxybuty1]-a,a-di- methylbenzenacetat i 20 ml absolut ethanol sættes 10 ml
O
DK 153709B
8 af en 50%'s natriumhydroxidopløsning, og blandingen holdes under tilbagesvaling i 3 1/2 time, hvorefter den inddampes til et fast stof, og der tilsættes den mindst mulige mængde methanol til opløsning af remanensen. Derefter til-5 sættes 10%'s vandig HC1, indtil pH-værdien er 7, methano-len fjernes ved afdampning, og 25 ml vand tilsættes. Ved omkrystallisering af det fremkomne bundfald fra methanol/-butanon fås 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]--l-hydroxybutyl]-a,a-dimethylbenzeneddikesyre med smp.
-10 195-197°C.
EKSEMPEL 3
Fremstilling af udgangsprodukt (A) Til 700 ml carbondisulfid indeholdende 36,5 g 15 (0,254 mol) 4-chlorbutyrylchlorid sættes 74,5 g (0,56 mol) aluminiumchlorid under omrøring ved -10°C, og omrøringen fortsættes i ca. 15 minutter ved ca. 25°C, hvorpå blandingen igen afkøles til 5°C og tilsættes 48,4 g (0,294 mol) ethyl-a-dimethylphenylacetat i 100 ml carbondisulfid. Reak-20 tionsblandingen omrøres i isbad i 3 1/2 time, og derefter i 15 1/2 time ved 25°C, hvorefter den hældes ud i HC1/-isvand og ekstraheres med chloroform. Ekstrakten vaskes med fortyndet natriumcarbonat-opløsning, vand og mættet natriumchlorid-opløsning, tørres over magnesiumsulfat og 25 inddampes, hvilket giver ethyl-4-(4-chlor-l-oxobutyl)-α,α--dimethylphenylacetat som et fast stof.
(B) En blanding af 4,5 g (0,0163 mol) 4-(a,a-di-phenyl)-piperidinmethanol, 6,1 g (0,0205 mol) ethyl-4- -(4-chlor-l-oxobutyl)-a,a-dimethylphenylacetat, 5 g (0,05 30 mol) kaliumbicarbonat og 0,05 g kaliumiodid i 50 ml toluen omrøres og holdes under tilbagesvaling i 72 timer, hvorpå den filtreres. Til filtratet sættes ether og derefter ethe-risk hydrogenchlorid, og det herved fremkomne bundfald samles og omkrystalliseres flere gange fra methanol/butanon 35 og butanon, hvilket giver ethyl-4-[4-[4-(hydroxydiphenylmethyl) -1-piperidinyl]-l-oxobutyl]-α,α-dimethylbenzenace-tat-hydrochlorid med smp. 205,5-208°C.
9 2.DK 1537098 · Ο
De her omhandlede forbindelsers fremragende virkning som antihistaminer sammenlignet med kendte forbindelser fremgår af de følgende forsøg, der ær gennem-5 ført på marsvin.
Der anvendes dels forbindelse I, a- (p-ctert.-butylphenyl)-4-(a-hydroxy-a-phenylbenzyl)-1-piperidin-butanol, som er en kendt forbindelse, der er fremstillet som beskrevet i eksempel 1 i USA-pateent-10 skrift nr. 3.878.217, dels forbindelse II, 4—[4— -[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxy-butyl]-a,a-dimethylbenzeneddikesyre, som ér fremstillet ifølge opfindelsen som beskrevet i eksempels.
De to forbindelser afprøves for deres 15 antihistamin-virkning overfor med histamin-di- phosphat fremkaldte hudvabler hos marsvin (1,0 μg pr. vabel). De to forbindelser indgives intravenøst i en dosis på 0,8 mg pr. kg i begge tilfælde.
Ved afprøvning på denne måde udviser for-20 bindelse I sin antihistamin-virkning gradvist og når maksimal effekt (85%'s inhibering) 240 minutter efter indgivelsen. I modsætning hertil fremkalder forbindelse II en hurtigt indtrædende virkning mod de histamin-inducerede vabler og når sin 25 maksimale effekt (90%'s inhibering) allerede 30 minutter efter indgivelsen.
Det ses, at forbindelse II under de beskrevne betingelser er langt den hurtigst virkende antihistaminsk virksomme forbindelse, hvorfor den 30 må anses for at have en overraskende fordelagtig virkning i forhold til den kendte forbindelse, når der ønskes en hurtigt indtrædende virkning.
35
Claims (2)
1. Analogifremgangsmåde til fremstilling af 4-sub-stituerede piperidinoalkanolderivater af formlen (I) 6" Nr oh ch3 10 (CH2) 3-CH-^~~^-C-R3
3. CH hvor R er -COOH eller -COO-alkyl? hvor alkylgruppen indeholder 1-6 carbonatomer og er ligekædet eller forgrenet, eller farmaceutisk acceptable salte af disse forbindelser, 15 kendetegnet ved, at den tilsvarende alkanon reduceres selektivt, hvorefter, om ønsket, en fremstillet 3 forbindelse, hvori R er -COO-alkyl, omdannes til en for- 3 bmdelse, hvori R er -COOH, ved base-hydrolyse, og/eller den dannede forbindelse omdannes til et farmaceutisk accep-2o tabelt salt deraf.
2. Fremgangsmåde ifølge krav 1, kendetegnet ved, at der anvendes sådanne udgangsforbindelser, at den opnåede forbindelse bliver ethyl-4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-25 -hydroxybutyl]-α,α-dimethylbenzen-acetat eller 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxy-buty1]-u,a-dimethylbenzeneddikesyre. 1 35
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/028,813 US4254129A (en) | 1979-04-10 | 1979-04-10 | Piperidine derivatives |
US2881379 | 1979-04-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK132980A DK132980A (da) | 1980-10-11 |
DK153709B true DK153709B (da) | 1988-08-22 |
DK153709C DK153709C (da) | 1988-12-27 |
Family
ID=21845568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK132980A DK153709C (da) | 1979-04-10 | 1980-03-27 | Analogifremgangsmaade til fremstilling af 4-substituerede piperidinoalkanolderivater |
Country Status (19)
Country | Link |
---|---|
US (1) | US4254129A (da) |
JP (1) | JPS55141469A (da) |
AT (1) | AT376208B (da) |
AU (1) | AU531146B2 (da) |
BE (1) | BE882703A (da) |
CA (1) | CA1123438A (da) |
CH (1) | CH643245A5 (da) |
DE (1) | DE3007498A1 (da) |
DK (1) | DK153709C (da) |
ES (1) | ES489934A0 (da) |
FR (1) | FR2453854A1 (da) |
IL (1) | IL59158A (da) |
IT (1) | IT1143960B (da) |
NL (2) | NL190580C (da) |
NO (2) | NO154521C (da) |
NZ (1) | NZ192653A (da) |
PH (1) | PH17023A (da) |
SE (1) | SE448726B (da) |
ZA (1) | ZA80332B (da) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240018A1 (es) * | 1987-10-07 | 1990-01-31 | Merrell Pharma Inc | Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol. |
US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
CN1053570C (zh) | 1987-10-07 | 2000-06-21 | 默尔多药物公司 | 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法 |
US4908372A (en) * | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
AR245888A1 (es) * | 1989-01-23 | 1994-03-30 | Merrell Pharma Inc | Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol. |
DE3917241A1 (de) * | 1989-05-26 | 1990-11-29 | Schaper & Bruemmer Gmbh | 4-(hydroxydiphenylmethyl)-1-piperidyl-phenylalkan-derivate |
US5190029A (en) * | 1991-02-14 | 1993-03-02 | Virginia Commonwealth University | Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
US5182097A (en) * | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
TW198008B (da) * | 1991-04-08 | 1993-01-11 | Green Cross Corp | |
HU211019B (en) * | 1991-12-02 | 1995-09-28 | Richter Gedeon Vegyeszet | Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds |
NZ249286A (en) * | 1992-02-13 | 1996-02-27 | Merrell Dow Pharma | Piperidine-4-ylmethyl thiophene and thiazole derivatives and pharmaceutical compositions |
US5631375A (en) * | 1992-04-10 | 1997-05-20 | Merrell Pharmaceuticals, Inc. | Process for piperidine derivatives |
HU226561B1 (en) * | 1992-04-10 | 2009-04-28 | Merrell Dow Pharma | Process for preparation 4-diphenylmethyl piperidine derivatives and the novel intermediates thereof |
JPH07506828A (ja) * | 1992-05-11 | 1995-07-27 | メレルダウファーマス−ティカルズ インコーポレイテッド | 肝臓が損われた患者での抗ヒスタミン剤としてのターフェナジン誘導体の用途 |
ES2284740T3 (es) * | 1992-08-03 | 2007-11-16 | Sepracor Inc. | Carboxilato de terfenadina y el tratamiento de la irritacion cutanea. |
US5654433A (en) * | 1993-01-26 | 1997-08-05 | Merrell Pharmaceuticals Inc. | Process for piperidine derivatives |
US20020007068A1 (en) * | 1999-07-16 | 2002-01-17 | D'ambra Thomas E. | Piperidine derivatives and process for their production |
DK1026147T3 (da) * | 1993-06-24 | 2004-03-22 | Albany Molecular Res Inc | Forbindelser, der er anvendelige som mellemprodukter i fremstillingen af piperidinderivater |
US6147216A (en) * | 1993-06-25 | 2000-11-14 | Merrell Pharmaceuticals Inc. | Intermediates useful for the preparation of antihistaminic piperidine derivatives |
EP2261207A1 (en) | 1993-06-25 | 2010-12-15 | Aventisub II Inc. | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives |
WO1995010278A1 (en) * | 1993-10-15 | 1995-04-20 | Hoechst Marion Roussel, Inc. | Treatment of allergic disorders with terfenadine carboxylate |
EP0725639B1 (en) * | 1993-10-25 | 2000-11-15 | Merrell Pharmaceuticals Inc. | A stable pharmaceutical composition of terfenadine and ibuprofen |
CA2189000C (en) * | 1994-05-16 | 2002-08-13 | Mitsuo Nakamura | Process and diastereomeric salts useful for the optical resolution of racemic .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol and derivative compounds |
US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
WO1995031437A1 (en) | 1994-05-18 | 1995-11-23 | Hoechst Marrion Roussel, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof |
CN101337922A (zh) * | 1994-05-18 | 2009-01-07 | 阿温蒂斯药物公司 | 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法 |
HU221434B (en) | 1994-08-25 | 2002-10-28 | Merrell Pharma Inc | Substituted piperidines, pharmaceutical compositions containing them and their use |
WO1996026726A1 (en) * | 1995-02-28 | 1996-09-06 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
CN1183769A (zh) * | 1995-05-08 | 1998-06-03 | 赫彻斯特马里恩鲁斯公司 | α-(取代的烷基苯基)-4-(羟基二苯基甲基)-1-哌啶丁醇衍生物,其制备和其用作抗组胺剂、抗变应性剂和支气管扩张药的用途 |
US5574045A (en) * | 1995-06-06 | 1996-11-12 | Hoechst Marion Roussel, Inc. | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form |
US5906747A (en) * | 1995-11-13 | 1999-05-25 | Biosepra Inc. | Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates |
US6211199B1 (en) | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
US6201124B1 (en) * | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US6153754A (en) * | 1995-12-21 | 2000-11-28 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US5998439A (en) * | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
US5932571A (en) * | 1996-02-21 | 1999-08-03 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases |
US5922737A (en) * | 1996-02-21 | 1999-07-13 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases |
US5925761A (en) * | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
EP0864653B1 (de) * | 1997-03-11 | 2004-03-03 | Aventis Pharmaceuticals Inc. | Verfahren zur Herstellung von 4-(4-(4-(Hydroxydiphenyl)-1-piperidinyl)-1-hydroxybutyl)-alpha,alpha-dimenthylphenylessigsäure und phosphorylierter Derivate |
US6451815B1 (en) | 1997-08-14 | 2002-09-17 | Aventis Pharmaceuticals Inc. | Method of enhancing bioavailability of fexofenadine and its derivatives |
AU725811B2 (en) * | 1997-08-26 | 2000-10-19 | Aventisub Llc | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
ES2200260T3 (es) * | 1997-12-17 | 2004-03-01 | Aventis Pharma Deutschland Gmbh | Procedimiento para la alquilacion de derivados de alquil-o bencilciano en presencia de trialquilaminas o trialquifosfinas. |
DE69835103T2 (de) * | 1997-12-23 | 2006-12-21 | Schering Corp. | Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum |
US6194431B1 (en) | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
AU2007200674C1 (en) * | 1998-07-02 | 2011-02-24 | Aventisub Llc | Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof |
US6683094B2 (en) | 1998-07-02 | 2004-01-27 | Aventis Pharmaceuticals Inc. | Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
US6689898B2 (en) | 1998-07-02 | 2004-02-10 | Aventis Pharmaceuticals Inc. | Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
ATE485271T1 (de) * | 1998-07-02 | 2010-11-15 | Aventisub Ii Inc | Antihistaminische piperidinderivate und zwischenprodukte zu ihrer herstellung |
GB9822170D0 (en) * | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
IN191492B (da) * | 1999-05-25 | 2003-12-06 | Ranbaxy Lab Ltd | |
US6613906B1 (en) * | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
US6613907B2 (en) | 2000-11-08 | 2003-09-02 | Amr Technology, Inc. | Process for the production of piperidine derivatives with microorganisms |
CH695216A5 (de) * | 2001-02-23 | 2006-01-31 | Cilag Ag | Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes. |
HUP0400299A2 (en) * | 2001-04-09 | 2007-08-28 | Teva Pharma | Polymorphs of fexofenadine hydrochloride |
US20030021849A1 (en) * | 2001-04-09 | 2003-01-30 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
EP2261209A1 (en) | 2001-06-18 | 2010-12-15 | Dr. Reddy's Laboratories Ltd. | Novel crystalline forms of 4-[4-[4- hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenene acetic acid and its hydrochloride |
US7700779B2 (en) | 2001-06-18 | 2010-04-20 | Dr. Reddy's Laboratories Limited | Crystalline forms of fexofenadine and its hydrochloride |
US20030158227A1 (en) * | 2001-11-08 | 2003-08-21 | Barnaba Krochmal | Polymorphs of fexofenadine base |
AU2002357701A1 (en) * | 2001-11-08 | 2003-05-19 | Teva Pharmaceutical Industries Ltd. | Polymorphs of fexofenadine base |
US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
ES2239554T1 (es) * | 2002-06-10 | 2005-10-01 | Teva Pharmaceutical Industries Ltd. | Forma xvi polimorfica de hidrocloruro de fexofenadina. |
CN1741981A (zh) * | 2002-12-16 | 2006-03-01 | 兰贝克赛实验室有限公司 | 非索那汀的制备方法 |
CN1756743A (zh) * | 2003-01-31 | 2006-04-05 | 兰贝克赛实验室有限公司 | 制备弗克芬得的方法 |
US20050026890A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
GB0319935D0 (en) * | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
JP2007532687A (ja) * | 2004-04-26 | 2007-11-15 | テバ ファーマシューティカル インダストリーズ リミティド | フェキソフェナジン塩酸塩の結晶形およびその製造方法 |
WO2006008567A1 (en) * | 2004-06-18 | 2006-01-26 | Wockhardt Limited | Pharmaceutical compositions for piperidinoalkanol compounds |
ITMI20041568A1 (it) * | 2004-07-30 | 2004-10-30 | Dipharma Spa | "polimorfi di fexofenadina base" |
US7498345B2 (en) * | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US7498443B2 (en) * | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of carebastine |
EP1685106A2 (en) * | 2004-09-28 | 2006-08-02 | Teva Pharmaceutical Industries, Inc. | Fexofendadine crystal form and processes for its preparation thereof |
US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US20070020330A1 (en) * | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
MX2007006233A (es) | 2004-11-24 | 2007-11-23 | Medpointe Healthcare Inc | Composiciones que comprenden azelastina y metodos de uso de la misma. |
JP2008120684A (ja) * | 2005-03-07 | 2008-05-29 | Kumamoto Univ | 抗アレルギー薬 |
JP5133244B2 (ja) * | 2005-08-05 | 2013-01-30 | ルピン・リミテッド | フェキソフェナジンの経口用医薬懸濁組成物 |
US20070088065A1 (en) * | 2005-10-14 | 2007-04-19 | Jie Du | Metaxalone products, method of manufacture, and method of use |
US20080292584A1 (en) * | 2005-10-14 | 2008-11-27 | Mutual Pharmaceutical Company, Inc. | Metaxalone products, method of manufacture, and method of use |
WO2007049303A2 (en) * | 2005-10-28 | 2007-05-03 | Ind-Swift Laboratories Limited | An improved process for the preparation of highly pure fexofenadine |
EP1956906A4 (en) | 2005-11-09 | 2009-12-30 | Combinatorx Inc | METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES |
DOP2006000274A (es) * | 2005-12-14 | 2007-10-15 | Sanofi Aventis Us Llc | Formulación de suspensión de fexofenadina |
CN100443470C (zh) * | 2006-07-21 | 2008-12-17 | 杭州保灵有限公司 | 一种依巴斯汀的制备方法 |
ITMI20061492A1 (it) * | 2006-07-27 | 2008-01-28 | Archimica Srl | Processo per la preparazione di fexofenadina. |
ITMI20061491A1 (it) * | 2006-07-27 | 2008-01-28 | Archimica Srl | Processo per la preparazione di fexofenadina. |
WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
NZ608343A (en) | 2007-04-13 | 2014-09-26 | Southern Res Inst | Anti-angiogenic agents and methods of use |
ITMI20070987A1 (it) * | 2007-05-16 | 2008-11-17 | Dipharma Francis Srl | Procedimento per la preparazione di composti chetonici |
US20090076080A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched fexofenadine |
US20090306135A1 (en) | 2008-03-24 | 2009-12-10 | Mukesh Kumar Sharma | Stable amorphous fexofenadine hydrochloride |
US20090306025A1 (en) * | 2008-05-30 | 2009-12-10 | Fairfield Clinical Trials, Llc | Method and composition for skin inflammation and discoloration |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
CN101585805B (zh) * | 2009-06-06 | 2011-07-06 | 浙江大学宁波理工学院 | 一种抗过敏药物非索非那定盐酸盐的制备方法 |
EP2289867A3 (en) | 2009-08-19 | 2012-04-25 | Jubilant Organosys Limited | A process for producing 4-(4-halo-1-oxybutyl)-alpha,alpha-dimethylbenzene acetic acid or alkyl esters thereof |
CN101671292B (zh) * | 2009-10-10 | 2011-09-07 | 浙江大学宁波理工学院 | 盐酸非索非那定的合成方法 |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
EP2371817A1 (en) * | 2010-04-01 | 2011-10-05 | Arevipharma GmbH | Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof |
ES2403130B1 (es) | 2010-06-15 | 2014-09-29 | Chemelectiva S.R.L. | Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación |
CN103702961A (zh) | 2011-05-23 | 2014-04-02 | 赛诺菲 | 含有n-烷基的氘代化合物的制备方法 |
JP5362151B2 (ja) | 2011-09-29 | 2013-12-11 | 塩野義製薬株式会社 | Pgd2拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
CN102659667B (zh) * | 2012-04-20 | 2013-08-14 | 浙江启明药业有限公司 | 一种非索非那定关键中间体的合成方法 |
CN103333100B (zh) * | 2013-06-06 | 2016-04-06 | 池州东升药业有限公司 | 一种盐酸非索非那定的合成工艺 |
ITMI20131652A1 (it) | 2013-10-07 | 2015-04-08 | Dipharma Francis Srl | Procedimento per la purificazione di derivati dell'acido 2-fenil-2-metil-propanoico |
CN104557671B (zh) * | 2013-10-10 | 2018-04-13 | 池州东升药业有限公司 | 一种非索非那定及中间体的合成方法 |
EP2949321A1 (en) | 2014-05-26 | 2015-12-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer formulations of fexofenadine and montelukast |
ES2738630T3 (es) | 2015-01-22 | 2020-01-24 | Sanofi Aventis Deutschland | Procedimiento para la producción de 2-[4-(ciclopropanocarbonil)fenil]-2-metil-propanonitrilo |
PL3365327T3 (pl) | 2015-10-22 | 2020-05-18 | Sanofi-Aventis Deutschland Gmbh | Sposób wytwarzania feksofenadyny i związki pośrednie stosowane w tym sposobie |
GB202212656D0 (en) | 2022-08-31 | 2022-10-12 | Novumgen Ltd | An orodispersible tablet of fecofenadine and it process of preparation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1242169A (en) * | 1969-04-09 | 1971-08-11 | Ucb Sa | Piperidine derivatives |
ZA728544B (en) * | 1972-01-28 | 1974-02-27 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
US3965257A (en) * | 1972-01-28 | 1976-06-22 | Richardson-Merrell Inc. | Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions |
BE794598A (fr) * | 1972-01-28 | 1973-05-16 | Richardson Merrell Inc | Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation |
US3806526A (en) * | 1972-01-28 | 1974-04-23 | Richardson Merrell Inc | 1-aroylalkyl-4-diphenylmethyl piperidines |
BE794596A (fr) * | 1972-01-28 | 1973-05-16 | Richardson Merrell Inc | Piperidinoalcanone-oximes substituees et leur procede de preparation |
US3941795A (en) * | 1974-02-08 | 1976-03-02 | Richardson-Merrell Inc. | α-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES |
US3931197A (en) * | 1974-02-08 | 1976-01-06 | Richardson-Merrell Inc. | Substituted piperidine derivatives |
US3946022A (en) * | 1974-03-04 | 1976-03-23 | Richardson-Merrell Inc. | Piperidine derivatives |
US3922276A (en) * | 1974-12-11 | 1975-11-25 | Robins Co Inc A H | 1-Substituted-4-benzylidenepiperidines |
US3956296A (en) * | 1974-12-11 | 1976-05-11 | A. H. Robins Company, Incorporated | 1-Substituted-4-benzylpiperidines |
-
1979
- 1979-04-10 US US06/028,813 patent/US4254129A/en not_active Expired - Lifetime
-
1980
- 1980-01-18 NZ NZ192653A patent/NZ192653A/xx unknown
- 1980-01-18 IL IL59158A patent/IL59158A/xx unknown
- 1980-01-18 CA CA344,020A patent/CA1123438A/en not_active Expired
- 1980-01-21 ZA ZA00800332A patent/ZA80332B/xx unknown
- 1980-01-29 AU AU55016/80A patent/AU531146B2/en not_active Expired
- 1980-02-07 NL NL8000754A patent/NL190580C/xx not_active IP Right Cessation
- 1980-02-28 DE DE19803007498 patent/DE3007498A1/de active Granted
- 1980-03-05 CH CH174180A patent/CH643245A5/de not_active IP Right Cessation
- 1980-03-17 AT AT0144880A patent/AT376208B/de not_active IP Right Cessation
- 1980-03-24 IT IT48245/80A patent/IT1143960B/it active Protection Beyond IP Right Term
- 1980-03-26 ES ES489934A patent/ES489934A0/es active Granted
- 1980-03-27 DK DK132980A patent/DK153709C/da not_active IP Right Cessation
- 1980-03-28 PH PH23831A patent/PH17023A/en unknown
- 1980-04-08 SE SE8002634A patent/SE448726B/sv not_active IP Right Cessation
- 1980-04-09 NO NO801014A patent/NO154521C/no unknown
- 1980-04-09 FR FR8007992A patent/FR2453854A1/fr active Granted
- 1980-04-09 BE BE0/200161A patent/BE882703A/fr not_active IP Right Cessation
- 1980-04-09 JP JP4577180A patent/JPS55141469A/ja active Granted
-
1998
- 1998-04-08 NL NL980013C patent/NL980013I2/nl unknown
- 1998-05-29 NO NO1998017C patent/NO1998017I1/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK153709B (da) | Analogifremgangsmaade til fremstilling af 4-substituerede piperidinoalkanolderivater | |
DK160250B (da) | Analogifremgangsmaade til fremstilling af 4-substituerede piperidinoalkanon-derivater eller farmaceutisk acceptable salte deraf | |
FI81567C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara n-substituerade 4-oxipiperidinfoereningar. | |
US4285957A (en) | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof | |
NO148111B (no) | Materialsammensetning som utgjoeres av emulsjon av svovel i karbonmaterial og fremgangsmaate for fremstilling av saadan materialsammensetning | |
US3974158A (en) | 2-(Substituted anilino)methylmorpholines | |
NO803453L (no) | Fremgangsmaate ved fremstilling av piperidylbenzimidazolonderivater | |
US3518276A (en) | Substituted 1-benzoylpropyl-4-hydroxy-4-phenyl piperidine derivatives | |
US5596101A (en) | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | |
CS196893B1 (en) | 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines | |
IE43847B1 (en) | N-substituted phenyl-piperidine derivatives | |
NO147150B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive piperidiner. | |
DK149133B (da) | Analogifremgangsmaade til fremstilling af 2-(4-(diphenylmethylen)- l-piperidinyl)- eddikesyrer eller farmaceutisk acceptable salte heraf | |
US20040034104A1 (en) | 2,2-Diphenylbutanamide derivatives and medicines containing the same | |
CA2526540C (en) | Cyclicamino-phenyl sulfamate derivatives | |
US3575990A (en) | 4-ar3-1-(4-ar1-4-ar2-butyl)-4-hydroxy-piperidines | |
US4029790A (en) | 1-Benzoyl-2 or 4 [2-(4-phenyl-piperazino)-ethyl]-piperidines | |
CS195652B2 (en) | Method of producing new 4-diphenylmethylen-1-hydroxy-benzylpiperidines | |
CA1123440A (en) | 4-(naphthalenyloxy)piperidine derivatives | |
NO743347L (da) | ||
US2485662A (en) | Alpha-(aminoalkyl)-stilbenes | |
US4024264A (en) | Diphenylbutylpiperidines | |
US3816434A (en) | 4-(3-(4-phenyl-piperidino)-2-hydroxy-propoxy)-benzophenones | |
US4029786A (en) | Morpholine derivatives for treating depression | |
WO1997009983A1 (en) | Piperidine derivatives and processes for their production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CTFF | Application for supplementary protection certificate (spc) filed |
Free format text: CA 1997 00024, 970702 |
|
CTFG | Supplementary protection certificate (spc) issued |
Free format text: CA 1997 00024, 970702, EXPIRES: 20050327 |
|
PUP | Patent expired |